Microbiota-Inflammation-Brain Axis in Heart Failure: New Functional Food for the Prevention of undeRnutrition in Older
Recruiting now · Not applicable
Conditions studied: Atrial Fibrillation (AF), Heart Failure
In brief
The goal of this clinical trial is to learn if the AMBROSIA Bar helps prevent undernutrition and muscle loss in older adults with heart failure or atrial fibrillation. The main questions it aims to answer are: Does the AMBROSIA Bar help improve muscle mass and physical performance in older adults with heart conditions? What effects does the AMBROSIA Bar have on body composition, quality of life, inflammation, nutrition status, and gut microbiota? Researchers will compare people who assume the AMBROSIA Bar in addition to nutritional counseling to those who only receive nutritional counseling. Participants will: * Receive nutritional counseling and consume one AMBROSIA Bar per day for 6 months (intervention group) or receive nutritional counseling only (control group). * Receive clinical assessment at the moment of enrolment, after 3 months, and after 6 months * Give samples (blood, saliva, urine, and stool) and complete questionnaires to check their nutrition, cognitive, and physical health
Key facts
- Study ID
- NCT07076329
- Run by
- Azienda Ospedaliero-Universitaria Careggi
- People needed
- 60
- Starts
- 2022-02-07
- Expected to finish
- 2025-09-30
- Last updated by the study team
- 2025-07-31
Who can join
Age: 70 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age >70 years;
- Caucasian ethnicity;
- Diagnosis of atrial fibrillation (AF) and/or heart failure (HF);
- Normal nutritional status or at risk of malnutrition;
- Adherence to Mediterranean diet
You may not qualify if…
- Obesity (BMI >30 Kg/m2);
- Underweight (BMI <18.5 Kg/m2);
- Use of antibiotics, corticosteroids and immune-suppressors in the last 6 months;
- Immunodeficiency;
- Trip to exotic areas in the last 12 months;
- Recent (<3 months) major surgical procedure;
- Uncontrolled diabetes mellitus;
- Active cancer;
- Chronic significant hepatic diseases;
- Chronic renal failure (KDIGO stages 4-5);
- Dementia and severe mental diseases;
- Other conditions interfering with autonomous drugs assumption;
- Chronic use of NSAIDs;
- Relevant history of allergy or infectious diseases
Where it is running
- Azienda Ospedaliera Universitaria Careggi — Florence, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.